The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often due to the fear of pain from needle sticks and a reluctance to visit medical facilities where there's a perceived risk of encountering illness. Now, a virtually pain-free, low-cost, easy-to-use, whole blood and plasma collection and dispensing system solves the problem of the physical pain of a traditional blood draw, making it easier, cheaper, and faster to potentially receive a diagnosis.

RedDrop Dx’s (Fort Collins, CO, USA) innovative blood collection device, RedDrop One, aims to enhance blood collection technology and patient care practices. With its user-centric design, RedDrop One eliminates many of the drawbacks associated with traditional blood collection methods, allowing for the collection of larger blood volumes more efficiently and with significantly less discomfort for the patient. This device is designed to fulfill the requirements of both healthcare professionals and patients by facilitating a more streamlined and less painful blood collection procedure. A clinical study involving 100 participants validated the efficacy of RedDrop One for self-sampling, showcasing an impressive 97% success rate when users adhered to the provided instructions.

RedDrop One's virtually painless, cost-efficient, and easy-to-use system is adaptable for a wide range of settings, including home healthcare, point-of-care applications, centralized labs, and decentralized clinical trials. This innovative device has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for prescription use, marking a significant advancement in blood collection practices and patient care.

“Receiving FDA Class II medical device clearance for RedDrop One, our industry-leading solution, allows us to play a crucial role in improving patient care by making blood collection more accessible, reliable, less painful, and with the highest quality,” said Kris Buchanan, CEO and co-founder of RedDrop Dx. “This is particularly important for supporting decentralized clinical trials and a variety of testing applications, where our technology can help overcome common obstacles related to phlebotomy and ensure timely access to essential tests. Demand for RedDrop One has never been higher as the industry has become more aware of our breakthrough technology. We look forward to leading the industry and realizing the potential of remote testing.”

Source:
https://www.labmedica.com/molecular-diagnostics/articles/294800709/upgraded-syndromic-testing-analyzer-enables-remote-test-results-access.html